Evidence map›Paper›PMID 34882517›Full record

ArticleExpert opinion on biological therapy2022

Mechanism of Action of Mesenchymal Stem Cells (MSCs): impact of delivery method.

Luiza L Bagno, Alessandro G Salerno, Wayne Balkan, Joshua M Hare

Open access · greenAbstract read
In one paragraph

Article in Expert opinion on biological therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Article
  8. The Landscape of Advanced Therapy Medicinal Products in Slovenian Transfusion Medicine: A Review of Past and Future Outlook.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2026
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Luiza L BagnoInterdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL, USA.ORCID 0000-0002-3112-4079
Alessandro G SalernoInterdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL, USA.ORCID 0000-0002-7688-5904
Wayne BalkanInterdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL, USA.ORCID 0000-0003-0405-0489
Joshua M HareInterdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL, USA.ORCID 0000-0002-7751-5032
University of Miami · US

Funding

ROLE OF Rac AND REACTIVE OXYGEN SPECIES IN KAPOSI'S SARCOMA VIRAL ONCOGENESISR01CA136387 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI SHEMBADE, NOULA DATTU · 2010 to 2024
$7.1M
Cardioprotective Effect of Growth Hormone Releasing HormoneR01HL107110 · NHLBI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI HARE, JOSHUA M · 2011 to 2020
$5.9M
Cell Based Therapy for Non-Ischemic Dilated CardiomyopathyUM1HL113460 · NHLBI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI HARE, JOSHUA M · 2012 to 2018
$4.3M
Cellular Cardiomyoplasty for Chronic Heart FailureR01HL084275 · NHLBI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI HARE, JOSHUA M · 2007 to 2016
$3.8M
1/2 Allogeneic Human Mesenchymal Stem Cell (MSC) Injection in Patients with Hypoplastic Left Heart Syndrome: A Phase IIb Clinical TrialUH3HL148318 · NHLBI · LURIE CHILDREN'S HOSPITAL OF CHICAGO · PI BERGER, STUART, HARE, JOSHUA M · 2021 to 2024
$3.5M
Mesenchymal stem cell therapy for endothelial dysfunction in diabetesR01HL134558 · NHLBI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI HARE, JOSHUA M · 2016 to 2020
$3.2M
Stem Cells for Dilated CardiomyopathyR01HL110737 · NHLBI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI HARE, JOSHUA M · 2011 to 2015
$3.2M
NCI NIH HHS R01 CA136387NHLBI NIH HHS HHSN268201600012CNHLBI NIH HHS R01 HL084275NHLBI NIH HHS R01 HL107110NHLBI NIH HHS R01 HL110737NHLBI NIH HHS R01 HL134558NHLBI NIH HHS UH3 HL148318NHLBI NIH HHS UM1 HL113460
6 · The paper itself

Abstract

introductionMesenchymal stromal cells (MSCs; AKA mesenchymal stem cells) stimulate healing and reduce inflammation. Promising therapeutic responses are seen in many late-phase clinical trials, but others have not satisfied their primary endpoints, making translation of MSCs into clinical practice difficult. These inconsistencies may be related to the route of MSC delivery, lack of product optimization, or varying background therapies received in clinical trials over time. AREAS COVERED: Here we discuss the different routes of MSC delivery, highlighting the proposed mechanism(s) of therapeutic action as well as potential safety concerns. PubMed search criteria used: MSC plus: local administration; routes of administration; delivery methods; mechanism of action; therapy in different diseases. EXPERT OPINION: Direct injection of MSCs using a controlled local delivery approach appears to have benefits in certain disease states, but further studies are required to make definitive conclusions regarding the superiority of one delivery method over another.

Indexed as

Mesenchymal Stem CellsMesenchymal Stem Cell TransplantationHumansWound HealingLocal InjectionMechanism of ActionMesenchymal Stem CellsMscs

Identifiers

PMID34882517
PMCPMC8934282
OpenAlexW4200337346

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.